(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Thursday, announced additional clinical data supporting the efficacy of its investigational treatment, QRX003, in Netherton Syndrome.
QRX003, a novel topical treatment, is being evaluated in multiple ongoing studies for its potential to treat Netherton Syndrome, a rare and severe skin disorder caused by a mutation in the SPINK5 gene. In the latest data, Quoin shared results from a subject who was dosed twice daily with QRX003 in an open-label study. After 12 weeks of treatment, the subject showed significant clinical improvements.
These included a decrease in the Modified Ichthyosis Area of Severity Index or MIASI from baseline and improved Investigator's Global Assessment or IGA scores.
However, four weeks after discontinuation of treatment, all clinical benefits were reversed, returning the disease to baseline status.
This underscores the importance of ongoing treatment with QRX003 for sustained clinical outcomes.
Dr. Michael Myers, CEO of Quoin Pharmaceuticals, said, "These results provide strong evidence of QRX003's mechanism of action and reinforce the need for chronic treatment to maintain positive clinical outcomes. Our commitment to advancing QRX003 toward approval remains unwavering, as we aim to address a significant unmet need in the Netherton Syndrome community."
Quoin is advancing multiple clinical trials and aims to file a New Drug Application or NDA for QRX003 as the first approved treatment for Netherton Syndrome.
The company remains focused on expanding its clinical data package to support regulatory submission and improve patient outcomes.
Currently, QNRX is trading at $0.44 down by 24.94%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
